评估去麦芽糖铁和羧基麦芽糖铁治疗挪威炎症性肠病合并缺铁性贫血患者的成本效用数据集

数据集获取（Figshare）

• 源站标题：Evaluating the cost-utility of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in Norway
• DOI：10.6084/m9.figshare.28071636.v2
• 发布日期：2025-02-17
• 文件数：2 个
• 文件总体积：43.86 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Evaluating_the_cost-utility_of_ferric_derisomaltose_versus_ferric_carboxymaltose_in_patients_with_inflammatory_bowel_disease_and_iron_deficiency_anaemia_in_Norway/28071636

命令行下载

curl -L -o "ijme_a_2444833_sm0356.docx" "https://ndownloader.figshare.com/files/52420195"
curl -L -o "ijme_a_2444833_sm0968.docx" "https://ndownloader.figshare.com/files/51329214"

文件清单

• ijme_a_2444833_sm0356.docx（14.41 KB）
• ijme_a_2444833_sm0968.docx（29.45 KB）

文件总体积 43.86 KB（源站 API 实测）。

数据说明

Iron deficiency anemia (IDA) is among the most common extraintestinal sequelae of inflammatory bowel disease (IBD). Intravenous iron is often the preferred treatment in patients with active inflammation with or without active bleeding, iron malabsorption, or intolerance to oral iron. The aim of the present study was to evaluate the cost-utility of ferric derisomaltose (FDI) versus ferric carboyxymaltose (FCM) in patients with IBD and IDA in Norway.
A published patient-level simulation model was used to evaluate the cost-utility of FDI versus FCM in patients with IBD and IDA from a Norwegian national payer perspective. Iron need was modelled based on bivariate distributions of hemoglobin and bodyweight combined with simplified tables of iron need from the FDI and FCM summaries of product characteristics. Patient characteristics and disease-related quality of life data were obtained from the PHOSPHARE-IBD trial. Cost-utility was evaluated in Norwegian Kroner (NOK) over a five-year time horizon.
Patients required 1.64 fewer infusions of FDI than FCM over five years (5.62 versus 7.26), corresponding to 0.41 fewer infusions per treatment course. The reduction in the number of infusions resulted in cost savings of NOK 5,236 (NOK 35,830 with FDI versus NOK 41,066 with FCM). The need for phosphate testing in patients treated with FCM resulted in further cost savings with FDI (no costs with FDI versus NOK 4,470 with FCM). Total cost savings with FDI were therefore NOK 9,707. FDI also increased quality-adjusted life expectancy by 0.071 quality-adjusted life years (QALYs) driven by reduced incidence of hypophosphatemia and fewer interactions with the healthcare system.
FDI resulted in cost savings and improved quality-adjusted life expectancy versus FCM in patients with IDA and IBD in Norway. FDI therefore represents the economically preferable iron formulation in Norwegian patients with IBD and IDA in whom it is indicated.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.28071636.v2（source: https://tandf.figshare.com/articles/dataset/Evaluating_the_cost-utility_of_ferric_derisomaltose_versus_ferric_carboxymaltose_in_patients_with_inflammatory_bowel_disease_and_iron_deficiency_anaemia_in_Norway/28071636）。